ABIVAX Société Anonyme (NASDAQ: ABVX) is now covered by analysts at Guggenheim. They set a "buy" rating and a $50.00 price target on the stock.
ABIVAX Société Anonyme (NASDAQ: ABVX) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $42.00 price target on the stock.
ABIVAX Société Anonyme (NASDAQ: ABVX) had its price target raised by analysts at Morgan Stanley from $15.00 to $16.00. They now have an "equal weight" rating on the stock.
Sofinnova Investments Appoints Troy Ignelzi as Executive Advisor
Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn’s and Colitis Organization (ECCO)